Seeking Alpha

Seeking Alpha Portfolio App for iPad

3,667 people get BIIB articles and Market Currents by email alert.

Get email alerts on BIIB »

BIIB

Biogen Idec Inc.

6/20/2013, 2:56 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 12, 9:59 AM Biogen (BIIB -2.7%) slides after Citi analyst Yaron Werber raises concerns about regulatory data protection (previous) for Tecfidera in Europe. Weber also believes prescriptions (previous) may be overstated by 31%. The shares are downgraded from Buy to Hold. See SA contributor Brian Wilson's recent piece for a discussion of the Tecfidera prescription debate (Also: Cowen warns on possible Tecfidera double-counting) Comment! [Healthcare, On the Move]
Thursday, May 30, 9:34 AM Biogen (BIIB -1.2%) expects to delay the EU launch of its Tecfidera multiple sclerosis drug until H2, as the company wants to make the treatment's data protection clearer so that it can potentially receive longer patent protection. Biogen has already launched Tecfidera in the U.S.; the medicine is expected to receive EU clearance this quarter. 1 Comment [Healthcare]
Tuesday, May 21, 1:50 PM Biogen (BIIB +3.6%) submits Biologics License Application to the FDA for the approval of its injectable drug candidate Plegridy for the treatment of multiple sclerosis. The company says the application is supported by data from year one of a two year Phase 3 study which "met all primary and secondary endpoints." In March, BIIB said the drug cut annual relapse rates by 36% and analysts say it could generate revenue of $318M by 2017. (PR) Comment! [Healthcare, On the Move]
Monday, May 13, 4:11 PM Biogen-Idec (BIIB +4.5%) finishes the day solidly higher after announcing that the FDA has accepted its Biologics License Application for the marketing approval of Elocate, a treatment for hemophilia A. With the acceptance BIIB now has product candidates under review for both hemophilia A and B. Comment! [Healthcare, On the Move]
Monday, April 29, 10:28 AM Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations. Comment! [Healthcare, On the Move]
Thursday, April 25, 7:47 AM More on Biogen's (BIIB) Q1: Revenue gains driven by 13% Y/Y growth of AVONEX. RITUXAN revenues reduced by $42M for damages awarded to Genentech. FAMPRYA and FUMADERM sales up 25%. Corporate partner revenues were $22M versus $3M in the comparable period last year. FY2013 guidance: revenue growth of between 16-18% and non-GAAP EPS of between $7.80-7.90. Analysts expect EPS of $7.79. Shares +2.8% premarket. (PR) Comment! [Healthcare, Earnings, On the Move]
Thursday, April 25, 6:31 AM Biogen Idec (BIIB): Q1 EPS of $1.97 beats by $0.36. Revenue of $1.4B (+10% Y/Y) misses by $0.01B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Tuesday, April 23, 7:51 AM Isis Pharmaceuticals (ISIS) initiates a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. The company will get $3.5M from Biogen (BIIB) upon dosing the first infant next month. Comment! [Healthcare]
Monday, April 22, 12:12 PM Biogen (BIIB +5.8%) rises after ICI analyst Mark Schoenebaum says the company's Tecfidera multiple sclerosis drug seems to be "crushing" its competitors. Following just a week on the market, Tecfidera's sales have achieved the same level that Novartis' (NVS) Gilenya reached after three months. However, Schoenebaum warns that it's still too early to make any definitive conclusions about Tecfidera. Comment! [Healthcare, On the Move]
Wednesday, April 17, 5:15 PM S&P takes Biogen (BIIB) further into investment grade territory, raising the firm's corporate credit rating to A- with a stable outlook. Three approved multiple sclerosis treatments and "no significant patent expirations in the intermediate term" equate to "minimal" financial risk. Comment! [Healthcare]
Tuesday, April 16, 2:05 PM Biogen Idec (BIIB +1.2%) and Roche's (RHHBY.PK) Genetech lose their appeal made in a patent infringement case against GlaxoSmithKline (GSK -0.1%). The Court upheld the interpretation of a BIIB patent covering the cancer drug Arzerra, ruling that GSK didn't infringe upon the patent. Comment! [Healthcare]
Friday, April 12, 10:59 AM Elan's (ELN -1.3%) shareholders have overwhelmingly approved a plan to buy back $1B in stock following the sale of Tsabri to Biogen Idec (BIIB +2.4%), as speculation mounts that an earlier takeover indication by Royalty Pharma might be sweetened. Royalty approached ELN in February with an $11 per share potential offer, valuing the company at $6.55B, which was rejected by ELN. Last week, Ireland's Takeover Panel told the pharmaceutical investor to either step up and announce an official takeover offer for the company by May 10, or walk away. Comment! [Healthcare, Global & FX, M&A]
Friday, April 12, 10:33 AM Biogen Idec (BIIB +4%) moves higher after BofA/ Merrill Lynch upgrades the shares to Buy from Neutral. Price target raised to $246 from $187. Comment! [On the Move, Healthcare]
Tuesday, April 2, 6:08 PM Biogen Idec (BIIB) completes its purchase of Elan's (ELN) interest in Tysabri, gaining full strategic, commercial and decision-making rights to the relapsing MS drug treatment. [BIIB plans to give further details and updated financial guidance during it's upcoming Q1 earnings announcement. Shares +0.3% AH. Comment! [Healthcare, M&A]

1
2
3
4
5
6
...
10
Next Page